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A B S T R A C T
The aim of this study was to determine if insertion-deletion polymorphism of angiotensin-converting enzyme is a risk
factor for the development of preeclampsia. Sixty women with preeclampsia and 50 normotensive pregnant women were
included in this study. Preeclampsia was defined as blood pressure > 140/90 mmHg in a previously normotensive wo-
men with proteinuria >300 mg/L in a 24-hours. Twelve women also had preeclampsia in previous pregnancy. The geno-
typing of polymorphism in the intron 16 of the angiotensin-converting enzyme was performed by the polymerase chain re-
action followed by the agarose electrophoresis. The patients were divided into three groups according to the presence (I)
or absence (D) of insertional polymorphism (II, ID, and DD). Genotype distribution and allele frequencies were compared
by Mantel-Haenszel c2 testing. The frequency of DD genotype was not significantly higher in women with preeclampsia
(26/60)than in the control group (14/50, p=0.096). The D allele frequency was significantly higher in 17 women with
preeclampsias who required delivery before 34 weeks of pregnancy (0.735), than in 43 women in whom obstetric compli-
cations took place after 34 weeks of pregnancy (0.56, p=0.036). The D allele frequency was 0.83 in women having recur-
rent preeclampsia, i.e. significantly higher compared with women, who were for the first time, experienced preeclampsia
(0.57, p=0.013). This study showed a significantly positive association between D allele frequency and risk of recurrent
preeclampsia and preterm delivery before 34 weeks of pregnancy. The deletion genotype could be an important contribut-
ing factor for an early onset and recurrent preeclampsia.
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Introduction
Preeclampsia (PE) is a heterogeneous disorder which
is characterized by hypertension and proteinuria after 20
weeks of gestation. The PE is the major cause of mater-
nal and perinatal morbidity with an estimated incidence
between 5–7% in pregnant population1. The cause of PE
remains unknown although genetic factors, placenta,
diet, parity, race, maternal weight and enviroment all
play a role2,3.
The renin-angiotensin-aldosterone system (RAS) plays
the central role in blood pressure control4. All compo-
nents of RAS, angiotensinogen, angiotensin II, aldostero-
ne and plasma renin activity are increased during the
normal pregnancy. Despite the increase, hypertension
does not develop in normal pregnancy because blood ves-
sels do not respond to angiotensin II5. Angiotensin-con-
verting enzyme (ACE), which is an important component
of RAS, plays a key role in the regulation of vascular tone
and circulatory homeostasis by converting angiotensin I
to angiotensin II and by inactivating bradykinin2,6. It has
been shown that PE can be caused by polymorphism-in-
duced altered expression in renin-angiotensin-aldosteron
system genes7. The ACE I/D polymorphism contributed
for about 50% of total phenotypic variance of the serum
levels, with a D allele highest effect2. Several genetic
studies showed that insertion-deletion polymorphism of
ACE has an important role in pathogenesis of experien-
tal and human hypertension2,8. The recently published
studies have investigated the association between inser-
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tion-deletion angiotensin-converting gene polymorphism
and preeclampsia, showing conflicting results between
investigated population of the different ethnic origin9–13.
The aim of our study was to investigate the associa-
tion of ACE insertion-deletion gene polymorphism with
preeclampsia and adverse pregnancy outcome in our
study population.
Patients and Methods
The study included 60 women with singleton preg-
nancy and preeclampsia recruited at the Department of
Perinatal Medicine, »Sveti Duh« Hospital in Zagreb,
Croatia between January 2000 and December 2005. The
control group consisted of 50 age- and parity-matched
normotensive women who had at least one normal deliv-
ery beyond 37 weeks of pregnancy. Control participants
were age and parity matched. Informed consent was ob-
tained from all study subjects and Hospital Ethics Com-
mittee approved the study.
Preeclampsia was defined as an increase in blood
pressure of 140/90 mmHg on two separate occasions 6
hours apart in previously normotensive women with pro-
tenuria of > 300 mg/L per 24 hours after 20 weeks of ges-
tation1. Women with history of chronic hypertension, di-
abetes mellitus, hyperthyroidism, chronic renal disease,
collagen disorders, and cardiovascular disease were ex-
cluded from the study.
Angiotensin-converting enzyme
insertion-deletion genotypining
The whole blood was collected in tubes containing et-
hylenediaminetetraacetic acid (EDTA). DNA was isola-
ted by a standard NaCl extraction methode14. Amplifica-
tion was carried out in a total volume of 50 mL containing
0.3 mg of genomic DNA, 0.2 mmol/L dNTPs, 0.2 mmol/L of
each primer in polymerase chain reaction (PCR) buffer
and 1 U DNA Taq-polymerase. Detection of insertion-de-
letion polymorphism of the ACE gene was carried out by
PCR amplification using sense primer 5’-CTG GAG ACC
ACT CCC ATC CTT TCT –3’, and antisense primer
5’-GAT GTG GCC ATC ACA TTC GTC AGA –3’. PCR
products from D alleles were 190bp long and from I alle-
les were 490 bp long. Additional amplification using in-
sertional primers was used to avoid misgenotyping of the
ID genotype due to preferential amplification of the D al-
lele 5’-TGG GAC CAG AGC GCC CGC CAC TAC-3’ and
5’- TCG CCA GCC CTC CCA TGC CCA TAA-3’, respecti-
vely. This PCR product was 335 bp long. Then, the PCR
products were electrophoresed in 1.5% agarose gel, and
visualised by ethidium bromide staining. The patients
were divided into three groups according to the combina-
tion of D and I alleles: genotype II, ID, and DD.
Statistical methods
The c² test was used to compare allele frequencies
and genotype distribution between women with preec-
lampsia and control group. Mantel-Haenszel c² test was
used to correlate the influence of the deletion allele and
genotype on clinical parameters. Fisher’s exact test was
applied when a small group was expected. The variance
between groups was expressed as odds ratio (OD) with
95% confidence interval (CI). Clinical variables were ex-
pressed as mean  standard deviation (SD), and were
compared by use of Student’s t-test. Differences were
considered statistically significant when P<0.05. SAS
software was used for statistical analysis (V8 SAS Insti-
tute, Cary, NC).
Results
There were significant differences in blood pressure
values, birth weight and weeks of delivery between wo-
men with preeclampsia and normotensive control group
(Table 1). As expected, women with preeclampsia had
significantly higher blood pressure. Also, in the group of
women with preeclampsia, the babies were born at signi-
ficantly earlier gestational age and with significantly
lower birth weight. The D and I allele frequency between
preeclamptic and control group was similar (Table 2).
The frequency of D allele was 0.633 in preeclamptic and
0.54 in control group (c2 =1.8378; p=0.1752; df=1).
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TABLE 1
CLINICAL CHARACTERISTICS OF WOMEN WITH PREECLAMPSIA AND CONTROL GROUP (MEAN VALUE SD)
Characteristics Preeclampsia (n=60) Control (n=50) p
Maternal age (years)  6.1
(19–45)
31.4  5.6
(19–45)
0.524
Gestational age at delivery (weeks) 36.5  3.4
(26–42)
39.22  1.04
(36–41)
<0.001
Birth weight (g) 2500  0.93 3590  0.56 <0.001
Blood pressure on admission (mm Hg)
Systolic 153,05  9.45 121.63  4.18 <0.001
Diastolic 99.14  8.05 77.13  4.77 <0.001
Proteinuria on admission(g/L) 1.28  0.94 —
Genotype distribution was quite similar in preeclam-
ptic and control group. The rate of DD genotype was slig-
htly, but not significantly higher in women with preec-
lampsia (43.3%) than in 28% in controls (OR 1.97, 95%CI
0.88–4.38, p=0.096). The D allele frequency was 0.735 in
17 women with preeclampsia who had delivery before 34
weeks of pregnancy because of obstetric complications
(OR 2.5 (95%Cl 1.03–6.05), compared to 43 women deliv-
ered after 34 weeks of pregnancy (0.56, p=0.036). Twelve
women also had preeclampsia in previous pregnancy. The
D allele prevalence was 0.83 in women who had preec-
lampsia in two consecutive pregnacies (OR 7.11 (95%Cl
1.4–36.117), Figure 1), which was significantly higher
compared with women, who were for the first time, expe-
rienced preeclampsia (0.57, p=0.013). In the group of wo-
men with previous and succesive pregnancy with preec-
lampsia, about 41% (5/12) had delivery before 34. weeks
of pregnancy. Four women had DD genotype, whereas
one women had ID genotype.
There was no significant difference between genotype
distribution and observed fetal growth restriction in
women with preeclampsia (OR=1.57 95%CI 0.5534–
4.4623). In women with preeclampsia, intrauterine fetal
death was detected in three cases. Two patients had II
genotype, while one had DD genotype. Abruption of pla-
centa was diagnosed in two women with preeclampsia
with II genotype.
Discussion and Conclusion
This study failed to confirm the association between
the angiotensin-converting enzyme deletion gene poly-
morphism and preeclampsia in our study group. Several
studies conducted among Chinese population suggested
that DD genotype was a risk factor, whereas insertion ge-
notype was a molecular marker of reduced risk for preec-
lampsia10,15,16. Kobashi et al.17 found no significant differ-
ences in the frequency of DD genotype between Japanese
women with preeclampsia and control group, although
the authors confirmed the higher frequency of DD geno-
type in the patients with positive history of preeclampsia
(25%) compared with the control group (8%). Choi et al.9
showed that I/D polymorphism of the ACE gene (rather
than angiotensinogen T174M and M235T genotypes)
was associated with the higher incidence of preeclampsia
in Korean woman. Several groups investigated the asso-
ciation of insertion-deletion polymorphism with preec-
lampsia in Caucasian population, but failed to prove sig-
nificant difference in allelic distribution between women
with preeclampsia and healthy controls12,18,19. According
to the results of previously published studies, it could be
concluded that association between the ACE gene inser-
tion/deletion polymorphism and preeclampsia depends
on the ethnic origin of investigated population20.
We found increased D allele frequency in women with
recurrent preeclampsia and those who required delivery
before 34 weeks of pregnancy. Several groups have inves-
tigated the frequency of D allele in carefully selected
groups of patients with early onset and recurrent forms
of preeclampsia. Mello et al.21 showed a significant asso-
ciation between DD genotype in women with history of
preeclampsia and the recurrence of an adverse obstetric
outcome such as preeclampsia and fetal growth restric-
tion affecting umbilical and uteroplacental flows. They
also showed that the treatment of women with DD geno-
type and history of preeclampsia with low-molecular-
-weight heparin reduced the recurrence of adverse clini-
cal outcomes, improving uteroplacental flow and mater-
nal blood pressure22. Another study implicated the influ-
ence of DD genotype on haemostasis balance in patients
with untreated hypertension, reflecting as an impair-
ment of endothelial function23. Moreover, ACE DD geno-
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Fig. 1. Distribution of deletion genotype in patients with previous
and successive pregnancy with preeclampsia.
TABLE 2
ANGIOTENSIN-CONVERTING ENZYME GENOTYPE DISTRIBUTION AND ALLELE FREQUENCIES
Group
Genotype Distribution Allele Frequency
N DD(%) ID (%) II (%) D I
Preeclampsia 60 26 24 10 0.636 0.364
Control 50 14 26 10 0.54 0.46
DD – deletion homozygote, ID – heterozygote, II – insertional homozygote
c2 =1.8378, p=0.1752, df=1
type could be also a risk factor for fetal first trimester
loss and for venous thromboembolism24,25.
Our study did not show that ACE gene insertion-dele-
tion polymorphism had a direct impact of the pathop-
hysiologic condition of preeclampsia, although moderate
positive associations cannot be ruled out. The results of
our study imply that deletion genotype in the group of
patients with positive history for preeclampsia could ha-
ve some importance. In such cases, the deletion genotype
could be an additional risk factor, acting synergistically
with other gene polymorphisms to increase the risk of
preeclampsia. A Croatia-wide study of women with re-
current preeclampsia and preeclampsia requiring deliv-
ery before 34 weeks of pregnancy should be performed in
order to explain the exact role of this and other genetic
polymorphisms as contributing factors for the develop-
ment of preeclampsia.
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ZNA^AJ GENOTIPIZACIJE POLIMORFIZMA ANGIOTENZIN I-KONVERTIRAJU]EG ENZIMA
KAO MOLEKULARNOG BILJEGA TRUDNO]OM POTAKNUTE HIPERTENZIJE
S A @ E T A K
Abnormalni procesi nastajanja i modeliranja krvnih `ila vode razvoju preeklampsije. Insercijsko/delecijski polimorfi-
zam angiotenzin I-konvertiraju}eg enzima, ima zna~ajnu ulogu u patogenezi velikog broja poreme}aja funkcije endotel-
nih `ila i patogenezi nekoliko oblika eksperimentalne i humane hipertenzije. Cilj istra`ivanja bio je utvrditi probirni
zna~aj insercijsko/delecijskog polimorfizma angiotenzin I-konvertiraju}eg enzima kao mogu}eg ~imbenika rizika raz-
voja hipertenzije u trudno}i; odrediti pojavnost I i D alela u preeklampti~noj i usporednoj skupini trudnica i usporediti
ove dvije skupine prema ishodu, trajanju trudno}e, paritetu, dobi, indeksu tjelesne te`ine, porodnoj gestacijskoj dobi i
porodnoj te`ini djeteta. Genomska DNA izolirana je iz pune krvi 60 preeklampti~nih trudnica i 50 normotenzivnih
trudnica. Preeklampsija se definira kao krvni tlak vi{i od 140/90 mmHg u odnosu na vrijednosti prije trudno}e i protei-
nurija >300 mg/L tijekom 24 sata nakon 20 tjedana trudno}e. Genotipizacija insercijsko/delecijskog polimorfizma unu-
tar introna 16 ACE gena provela se metodom lan~ane reakcije polimeraze i vizualizacijom elektroforezom u gelu aga-
roze. Usporedba genotipova i pojavnosti alela provela se Mantel-Haenszelovim c2 testom. Raspodjela I i D alela ACE
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polimorfizma izmedu usporedne i preeklampti~ne skupine nije se statisti~ki razlikovala. Zastupljenost trudnica s DD
genotipom u preeklampti~noj skupini je ve}a, ali ne statisti~ki zna~ajna, i iznosi 43,3%, dok 28% normotenzivnih trud-
nica ima isti genotip (p=0,096). Kod preeklampti~nih trudnica koje su rodile prije 34. tjedna trudno}e, raspodjela D
alela bila je statisti~ki zna~ajno vi{a i iznosila je 0.735 u odnosu na ostale (p=0,036). U preeklampti~noj skupini trudni-
ca koje su i u prethodnoj trudno}i imale preeklampsiju udio D alela iznosio je 0,83 (p=0,01). Nismo na{li statisti~ki zna-
~ajnu razliku izme|u pojavnosti odre|enog genotipa i intrauterinog zastoja rasta ploda u preeklampti~noj skupini. De-
lecijski polimorfizam nema direktnu ulogu u razvoju preeklampsije, me|utim odre|ene pozitivne sveze se ne mogu u
potpunosti isklju~iti. Na{e istra`ivanje je pokazalo statisti~ki zna~ajnu pozitivnu svezu izmedu pojavnosti D alela I rizi-
ka razvoja preeklampsije u sljede}oj trudno}i kod trudnica koje su u prethodnoj trudno}i imale preeklampsiju i poroda
prije 34. tjedna trudno}e kod preeklampti~nih trudnica. U ovakvim slu~ajevima delecijski genotip mogao bi biti dodatni
~imbenik rizika, koji djeluje sinergisti~ki s drugim genskim polimorfizimima, pove}avajuci rizik razvoja preeklampsije.
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